VEGFA and Miyoshi myopathy: Klaus Podar’s work with the selective-adhesion molecule (SAM) inhibitor Natalizumab, an anti-integrin-α4 monoclonal antibody, showed it prevents MM cell adhesion to the TME, disrupts pre-bound MM cells, inhibits VEGF-induced angiogenesis, impedes MM cell migration, and resensitizes MM cells to bortezomib [47].